ATC Group: R05CB06 Ambroxol

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of R05CB06 in the ATC hierarchy

Level Code Title
1 R Respiratory system
2 R05 Cough and cold preparations
3 R05C Expectorants, excl. combinations with cough suppressants
4 R05CB Mucolytics
5 R05CB06 Ambroxol

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.12 g

Active ingredients in R05CB06

Active Ingredient Description
Ambroxol

Ambroxol induces activation of the surfactant system by acting directly on the type II pneumocytes of the alveoles and the Clara cells in the region of the small airways. It promotes the formation and outward transfer of surface-active material in the alveolar and bronchial region of the foetal and adult lungs.

Related product monographs

Title Information Source Document Type  
FLUIBRON Syrup Υπουργείο Υγείας (CY) MPI, EU: SmPC
MEDOVENT Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
MUCOBROXOL Syrup Υπουργείο Υγείας (CY) MPI, EU: SmPC

Medicines in this ATC group

Finland (FI)

France (FR)

Japan (JP)

Mexico (MX)

Netherlands (NL)

South Africa (ZA)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.